FDA clears Pfizer’s potential eczema blockbuster
Pfizer’s Eucrisa has been cleared by the US Food and Drug Administration as a treatment for mild to moderate atopic dermatitis in patients two years of age and older.
Read More
Tag: crisaborole
Pfizer completes $5.2bn acquisition of Anacor
Pfizer has completed its acquisition of Silicon Valley biotech group Anacor securing access to its flagship non-steroidal topical PDE4 inhibitor crisaborole.
Read More
- GSK wins US approval for ROS1 lung cancer therapy
- Lundbeck secures FDA Fast Track for narcolepsy drug
- R1 Therapeutics begins global phase 2b trial of AP306 for hyperphosphatemia
- Mission Therapeutics divests MTX652 to Dimerix in deal worth up to $292 million
- Nouscom to present re‑treatment data in Lynch Syndrome at ESMO 2026
